pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
SHIONOGI · news · pharmadog
← back to SHIONOGI
News mentioning SHIONOGI
10
stories
23d
Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
biospace
24d
STAT+: AstraZeneca opens new Boston site
stat
24d
Shionogi makes $2B rare disease play with IntraBio buy
biospace
25d
Shionogi pays $2B to acquire a rare disease startup
biopharma dive
25d
Shionogi to pay $2B for IntraBio, a commercial rare disease biotech
endpoints
Sep 10, 26
Shionogi's stroke drug fails mid-stage; Bayer's Hyrnuo gets expanded label
endpoints
Jul 31, 26
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
biopharma dive
Jul 31, 26
Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
fiercebiotech
Jun 18, 26
Antifungal from F2G, Shionogi succeeds in Phase 3 study
endpoints
Jun 1, 26
Shionogi wins US approval for first pill to prevent Covid following exposure
endpoints
